Drug Search Results
More Filters [+]

Simeticone

Alternative Names: simeticone, espumisan
Latest Update: 2024-10-25
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Austria | Belgium | Bulgaria | Croatia | Cyprus | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Malta | New Zealand | Pakistan | Philippines | Poland | Portugal | Russia | Serbia | Singapore | South Africa | Spain | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Simeticone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Diarrhea|CHARGE Syndrome|Spasm

Phase 3: Constipation|Dyspepsia|Gastritis

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CO-161213141338-DHCT

P1

Completed

Healthy Volunteers

2019-12-26

27%

CO-150121160547-DHCT

P3

Completed

Dyspepsia|Gastritis

2016-10-01

NICEVIS Version 1.0

P2

Completed

Unknown

2014-04-24

2009-013049-27

P4

Completed

CHARGE Syndrome|Spasm

2011-10-06

Recent News Events